pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
semaglutide · news · pharmadog
← back to semaglutide
News mentioning semaglutide
26
stories
2d
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
2d
Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
biospace
3d
Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win
fiercebiotech
6d
Skye and Redx form new entity with $125M to advance fibrosis assets
fiercebiotech
15d
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
15d
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
15d
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
fiercebiotech
16d
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
22d
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
22d
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
biospace
22d
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
fiercebiotech
23d
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
fiercebiotech
28d
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
Jul 21, 26
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
Jul 17, 26
Compounders maintain a firm grip on the GLP-1 market
biopharma dive
Jul 9, 26
Opinion: Who benefits from classifying obesity as a disease?
stat
Jul 7, 26
Ebola outbreak exposes a fractured outbreak response system
stat
Jul 6, 26
STAT+: Online GLP-1 prescriptions are often fast, easy — and low on clinical oversight
stat
Jul 6, 26
Opinion: The smart way to regulate the peptide boom
stat
Jun 16, 26
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, Germany’s pricing plans, and more
stat
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
May 29, 26
Which vaccines will curb the Ebola outbreak? WHO debates
stat
May 29, 26
Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
stat
May 13, 26
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
stat
May 1, 26
STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more
stat
Apr 30, 26
STAT+: FDA wants to exclude weight loss drugs from a compounding list
stat
